Denis Moro‐Sibilot

32.8k total citations · 6 hit papers
282 papers, 10.5k citations indexed

About

Denis Moro‐Sibilot is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Denis Moro‐Sibilot has authored 282 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 231 papers in Pulmonary and Respiratory Medicine, 182 papers in Oncology and 38 papers in Molecular Biology. Recurrent topics in Denis Moro‐Sibilot's work include Lung Cancer Treatments and Mutations (188 papers), Lung Cancer Research Studies (89 papers) and Lung Cancer Diagnosis and Treatment (87 papers). Denis Moro‐Sibilot is often cited by papers focused on Lung Cancer Treatments and Mutations (188 papers), Lung Cancer Research Studies (89 papers) and Lung Cancer Diagnosis and Treatment (87 papers). Denis Moro‐Sibilot collaborates with scholars based in France, United States and Italy. Denis Moro‐Sibilot's co-authors include Fabrice Barlési, Federico Cappuzzo, Naoyuki Nogami, Francesco Orlandi, Daniil Stroyakovskiy, Robert M. Jotte, Delvys Rodríguez‐Abreu, Anthony Lee, Martin Reck and Christian A. Thomas and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Denis Moro‐Sibilot

266 papers receiving 10.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

2018 2.6k citations Federico Cappuzzo, Denis Moro‐Sibilot et al. profile →
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

2019 688 citations Federico Cappuzzo, Denis Moro‐Sibilot et al. profile →
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

2013 489 citations Julien Mazières, Solange Peters et al. profile →
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015 430 citations H. Léna, Denis Moro‐Sibilot et al. profile →
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

2019 319 citations Solange Peters, Shirish M. Gadgeel et al. profile →
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

2021 316 citations Federico Cappuzzo, Denis Moro‐Sibilot et al. profile →

Peers

Countries citing papers authored by Denis Moro‐Sibilot

Since Specialization

Citations

This map shows the geographic impact of Denis Moro‐Sibilot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Moro‐Sibilot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Moro‐Sibilot more than expected).

Fields of papers citing papers by Denis Moro‐Sibilot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Moro‐Sibilot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Moro‐Sibilot. The network helps show where Denis Moro‐Sibilot may publish in the future.

Co-authorship network of co-authors of Denis Moro‐Sibilot

This figure shows the co-authorship network connecting the top 25 collaborators of Denis Moro‐Sibilot. A scholar is included among the top collaborators of Denis Moro‐Sibilot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Moro‐Sibilot. Denis Moro‐Sibilot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial 2025 ·Translational Oncology ·Guénaëlle Levallet, Christian Créveuil, (unknown), Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Sylvie Lantuéjoul, Julien Mazières, Laurent Greillier, Clarisse Audigier-Valette, Emmanuel Bergot, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, Isabelle Monnet, Franck Morin, V. Gounant, Gérard Zalcman	1
2	STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial 2024 ·Lung Cancer ·(unknown), Simon Garinet, Caroline Léger, Fabrice Barlési, Julien Mazières, G. Jeannin, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Alexandra Langlais, Elodie Amour, (unknown), (unknown), Hélène Blons, Marie Wislez	2
3	Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel 2021 ·Journal for ImmunoTherapy of Cancer ·David R. Gandara, Martin Reck, Denis Moro‐Sibilot, Julien Mazières, Shirish M. Gadgeel, Stefanie Morris, Andrés F. Cardona, Diana Mendus, Marcus Ballinger, Achim Rittmeyer, Solange Peters	14
4	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project 2020 ·Lung Cancer ·Hélène Blons, (unknown), Jean‐Philippe Merlio, D. Debieuvre, Florence de Fraipont, Clarisse Audigier-Valette, Fabienne Escande, S. Hominal, (unknown), (unknown), L’Houcine Ouafik, Denis Moro‐Sibilot, Antoinette Lemoine, Alexandra Langlais, (unknown), Franck Morin, P.-J. Souquet, Fabrice Barlési, Jacques Cadranel, Michèle Beau‐Faller	7
5	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer 2020 ·Cancers ·Élisa Gobbini, Aurélie Swalduz, Matteo Giaj Levra, Sandra Ortiz‐Cuaran, Anne‐Claire Toffart, M. Pérol, Denis Moro‐Sibilot, Pierre Saintigny	26
6	Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer 2020 ·Cancers ·(unknown), Anne‐Claire Toffart, Matteo Giaj Levra, Denis Moro‐Sibilot, Élisa Gobbini	5
7	1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort 2020 ·Annals of Oncology ·Nicolas Girard, (unknown), M. Duruisseaux, Virginie Avrillon, Benoît Roch, Josiane Otto, J. Cadranel, (unknown), Denis Moro‐Sibilot, Thomas Egenod, R. Lamy, Jaafar Bennouna, Gérard Zalcman, Charles Ricordel, (unknown), (unknown), Benjamin Besse, (unknown), Virginie Westeel, Simon Baldacci	1
8	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial 2019 ·Clinical Cancer Research ·Guillaume Eberst, Amélie Anota, Arnaud Scherpereel, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, F. Rivière, I. Monnet, V. Gounant, Henri Janicot, Radj Gervais, (unknown), (unknown), Franck Morin, Gérard Zalcman, Virginie Westeel	15
9	Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO 2018 ·Revue des Maladies Respiratoires ·(unknown), Martine Antoine, Denis Moro‐Sibilot, C. Dayen, B. Mennecier, R. Gervais, Elodie Amour, B. Milleron, Franck Morin, Gérard Zalcman, Marie Wislez	11
10	Are all ALK rearrangements created equal 2017 ·Translational Cancer Research ·M. Duruisseaux, (unknown), Denis Moro‐Sibilot, Jacques Cadranel	1
11	Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial 2017 ·Annals of Oncology ·Gérard Zalcman, Julien Mazières, Laurent Greillier, (unknown), (unknown), Olivier Bylicki, I. Monnet, R. Corre, Clarisse Audigier-Valette, M. Locatelli-Sanchez, Olivier Molinier, Luc Thiberville, T. Urban, David Planchard, Catherine Ligeza‐Poisson, Elodie Amour, Franck Morin, Denis Moro‐Sibilot, Arnaud Scherpereel	12
12	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort 2015 ·Annals of Oncology ·Julien Mazières, Fabrice Barlési, Thomas Filleron, Benjamin Besse, I. Monnet, Michèle Beau‐Faller, Solange Peters, Éric Dansin, Martin Früh, Miklos Pless, Rafael Rosell, Marie Wislez, P. Fournel, Virginie Westeel, Federico Cappuzzo, Alexis B. Cortot, Denis Moro‐Sibilot, Julie Milia, Oliver Gautschi	219
13	Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity 2014 ·Clinical Cancer Research ·(unknown), Julien Laffaire, Sylvie Lantuéjoul, Denis Moro‐Sibilot, (unknown), François Arbib, Anne‐Claire Toffart, Fabien Petel, Pierre Hainaut, Sophie Rousseaux, Saadi Khochbin, Aurélien de Reyniès, Élisabeth Brambilla	32
14	Nouvelle perspective de traitement dans le cancer bronchique non à petites cellules (CBNPC). Place de l’afatinib : un inhibiteur oral et irréversible de la famille ErbB 2014 ·Bulletin du Cancer ·Marie Wislez, David Malka, Jaafar Bennouna, Laurent Mortier, René‐Jean Bensadoun, (unknown), Pascale Dielenseger, Jean‐Baptiste Rey, Denis Moro‐Sibilot, Florian Scotté	8
15	An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial 2012 ·Clinical Cancer Research ·Florence de Fraipont, Guénaëlle Levallet, Christian Créveuil, Emmanuel Bergot, Michèle Beau‐Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie‐Christine Favrot, D. Debieuvre, Denis Braun, Virginie Westeel, Élisabeth Quoix, Élisabeth Brambilla, Pierre Hainaut, Denis Moro‐Sibilot, Franck Morin, B. Milleron, Gérard Zalcman	46
16	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway 2012 ·Molecular Cancer Therapeutics ·Guénaëlle Levallet, Emmanuel Bergot, Martine Antoine, Christian Créveuil, Adriana O. Santos, (unknown), Florence de Fraipont, Élisabeth Brambilla, Jérôme Levallet, Franck Morin, Virginie Westeel, Marie Wislez, Élisabeth Quoix, D. Debieuvre, Fatéméh Dubois, Isabelle Rouquette, Jean-Louis Pujol, Denis Moro‐Sibilot, Jacques Camonis, Gérard Zalcman	74
17	Primary lung adenocarcinoma: characteristics by smoking habit and sex 2011 ·European Respiratory Journal ·Hélène Nagy-Mignotte, Pascale Guillem, Aurélien Vesin, (unknown), M. Colonna, Vincent Bonneterre, Pierre-Yves Brichon, Christian Brambilla, E Brambilla, Sylvie Lantuéjoul, Jean‐François Timsit, Denis Moro‐Sibilot	28
18	101: Identification of differential pathways in mucinous and non-mucinous subtypes of lung adenocarcinoma suggested new therapeutic strategies 2010 ·Bulletin du Cancer ·Amandine Hurbin, Benoît Busser, Élisabeth Brambilla, Denis Moro‐Sibilot, Martine Antoine, Virginie Poulot, Jean‐Luc Coll, Marie Wislez, J. Cadranel	2
19	Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non–Small Cell Lung Cancer 2008 ·Clinical Cancer Research ·Arnaud Van Den Broeck, Élisabeth Brambilla, Denis Moro‐Sibilot, Sylvie Lantuéjoul, Christian Brambilla, Béatrice Eymin, Saadi Khochbin, Sylvie Gazzéri	156
20	Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non à petites cellules (CBNPC) de stade IV ? 2007 ·Revue des Maladies Respiratoires ·Denis Moro‐Sibilot, (unknown), Gérard Zalcman, (unknown), (unknown), D. Debieuvre, (unknown), Jean‐François Morère	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact